Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
Kanaoka T, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kobayashi R, Fujikawa T, Tsurumi-Ikeya Y, Maeda A, Yanagi M, Toya Y, Umemura S. Kanaoka T, et al. Among authors: azushima k. Int J Mol Sci. 2013 Aug 16;14(8):16866-81. doi: 10.3390/ijms140816866. Int J Mol Sci. 2013. PMID: 23959116 Free PMC article. Clinical Trial.
Involvement of Runx3 in the basal transcriptional activation of the mouse angiotensin II type 1 receptor-associated protein gene.
Matsuda M, Tamura K, Wakui H, Dejima T, Maeda A, Ohsawa M, Kanaoka T, Haku S, Azushima K, Yamasaki H, Saito D, Hirose T, Maeshima Y, Nagashima Y, Umemura S. Matsuda M, et al. Among authors: azushima k. Physiol Genomics. 2011 Jul 27;43(14):884-94. doi: 10.1152/physiolgenomics.00005.2011. Epub 2011 May 17. Physiol Genomics. 2011. PMID: 21586669
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S. Maeda A, et al. Among authors: azushima k. Clin Exp Hypertens. 2012;34(4):249-57. doi: 10.3109/10641963.2012.681081. Epub 2012 May 9. Clin Exp Hypertens. 2012. PMID: 22571446 Free article. Clinical Trial.
Relationship of ambulatory blood pressure and the heart rate profile with renal function parameters in hypertensive patients with chronic kidney disease.
Kanaoka T, Tamura K, Ohsawa M, Yanagi M, Haku S, Wakui H, Maeda A, Dejima T, Azushima K, Mitsuhashi H, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S. Kanaoka T, et al. Among authors: azushima k. Clin Exp Hypertens. 2012;34(4):264-9. doi: 10.3109/10641963.2012.681082. Epub 2012 May 11. Clin Exp Hypertens. 2012. PMID: 22578052 Free article.
Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients.
Kanaoka T, Tamura K, Ohsawa M, Wakui H, Maeda A, Dejima T, Azushima K, Haku S, Mitsuhashi H, Yanagi M, Oshikawa J, Uneda K, Aoki K, Fujikawa T, Toya Y, Uchino K, Umemura S. Kanaoka T, et al. Among authors: azushima k. J Clin Hypertens (Greenwich). 2012 Aug;14(8):522-9. doi: 10.1111/j.1751-7176.2012.00640.x. Epub 2012 May 3. J Clin Hypertens (Greenwich). 2012. PMID: 22863160 Free PMC article. Clinical Trial.
The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap.
Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, Kanaoka T, Haku S, Uneda K, Masuda S, Azuma K, Shigenaga A, Koide Y, Tsurumi-Ikeya Y, Matsuda M, Toya Y, Tokita Y, Yamashita A, Umemura S. Tamura K, et al. Among authors: azushima k. Curr Pharm Des. 2013;19(17):3043-8. doi: 10.2174/1381612811319170010. Curr Pharm Des. 2013. PMID: 23176217 Review.
101 results